DBVT
USDDBV Technologies S.A. American Depositary Shares
Real-time Price
Price Chart
Key Metrics
Market Metrics
Open
$14.050
High
$15.010
Low
$14.050
Volume
0.07M
Company Fundamentals
Market Cap
521.2M
Industry
Biotechnology
Country
France
Trading Stats
Avg Volume
0.10M
Exchange
NCM
Currency
USD
52-Week Range
Related News
DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
Châtillon, France, November 4, 2025 DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, today
DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer
Chatillion, France, November 3, 2025 DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, today announced the
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of October 31, 2025
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of October 31, 2025 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE
DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors
Châtillon, France, October 30, 2025 DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors DBV Technologies (TRQX:DBVp), (the "Company" or "DBV"), a clinical-stage biopharmaceutical
DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting
Châtillon, France, October 30, 2025 DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, today announced upcoming
DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq
Châtillon, France, October 29, 2025 DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq DBV Technologies (TRQX:DBVp) (the "Company"), a clinical-stage
HC Wainwright & Co. Maintains Buy on DBV Technologies, Raises Price Target to $20
HC Wainwright & Co. analyst Andrew S. Fein maintains DBV Technologies with a Buy and raises the price target from $16 to $20.
Related Stocks
VALN
Valneva SE American Depositary Shares
CMMB
Chemomab Therapeutics Ltd. American Depositary Share
MRKR
Marker Therapeutics Inc.
LCTX
Lineage Cell Therapeutics Inc.
CLLS
Cellectis S.A. American Depositary Shares
Stay Updated
Set price alerts, get AI analysis updates and real-time market news.